Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or CMT research.
Breaking News for SORD Deficiency Patients
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
0 Comments